For Acadia’s Pimavanserin, The Second Time Is The Charm
This article was originally published in The Pink Sheet Daily
Executive Summary
Acadia’s serotonin 5-HT2A receptor blocker demonstrated efficacy in a Phase III trial in patients with Parkinson’s disease psychosis, giving the drug a second chance to reach the market. Pimavanserin previously failed to demonstrate efficacy in an original Phase III trial.
You may also be interested in...
Acadia’s Persistence With Pimavanserin In Parkinson’s Psychosis Pays Off
After meeting with FDA, Acadia announces it needs only one pivotal study for pimavanserin. The company has canceled a second study and expects to file at the end of 2014. Faster NDA pathway could mean launch a year earlier than expected.
Acadia’s Persistence With Pimavanserin In Parkinson’s Psychosis Pays Off
After meeting with FDA, Acadia announces it needs only one pivotal study for pimavanserin. The company has canceled a second study and expects to file at the end of 2014. Faster NDA pathway could mean launch a year earlier than expected.
Acadia Now Has The Cash To Finish Phase III On Its Own
After announcing promising Phase III data in late November, Acadia Pharmaceuticals conducted a private placement of nearly 20 million shares that will net the company $86.4 million in funds to continue running its Phase III program for pimavanserin in Parkinson’s disease psychosis.